MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2018 International Congress

    A novel mGlu4 PAM alleviates motor symptoms in primate models of PD and of LID

    D. Charvin, T. Di Paolo, E. Bezard, L. Gregoire, A. Takano, G. Duvey, E. Pioli, C. Halldin, R. Medori, F. Conquet (Plan-les-Ouates, Switzerland)

    Objective: Objective was to assess the therapeutic potential of our novel mGlu4 positive allosteric modulator (PAM), foliglurax, as an anti-parkinsonian treatment in gold-standard primate models.…
  • 2018 International Congress

    Clinical characteristics of turkish patients with Parkinson’s disease: A retrospective analysis of 428 patients

    B. Gonenli Kocer, E. Ozturk, S. Comoglu (Ankara, Turkey)

    Objective: To evaluate the demographic, motor and non-motor clinical characteristics of Turkish Parkinson’s disease (PD) patients in our Movement Disorders Outpatient Clinic. Background: Although PD…
  • 2018 International Congress

    Longitudinal observational study on late onset Parkinson’s disease over a decade

    S. Raha, L. Ebenezer (Bridgend, United Kingdom)

    Objective: 1. To analyse the outcome of Late onset Parkinson’s disease over ten year period. 2. To look for any relationship between Initial cognition to…
  • 2018 International Congress

    The effectiveness of boxing exercise in elderly patients including Parkinson’s disease patients

    N. Kawashima, M. Isogai, M. Matsuhashi, M. Komachi, H. Ikebe, A. Kumon, K. Miyashita, A. Sato, K. Hasegawa (Fujisawa, Japan)

    Objective: To clarify the effect of boxing exercise on balance, muscle strength and mobility in elderly patients with chronic disease including Parkinson’s disease (PD). Background:…
  • 2018 International Congress

    Evaluation of the interaction between safinamide and opicapone in Parkinson’s disease patients with fluctuations

    J. Garcia-Caldentey, MA. Prats-Sedano, I. Legarda-Ramirez, E. Estelrich-Peyret, B. Vives-Pastor, PJ. Garcia (Palma de Mallorca, Spain)

    Objective: To describe and to evaluate a Balearic ongoing Parkinson's disease (PD) Project to evaluate the efficacy and tolerance of the interaction between safinamide and…
  • 2018 International Congress

    Home based exercises to reduce falls in people with Parkinson’s disease: A randomized trial

    M. Morris, N. Taylor, J. McGinley, M. Danoudis, H. Menz (Bundoora, Australia)

    Objective: To measure the outcomes of a six week, twice weekly, home physiotherapy exercise and falls education program on falls, mobility and quality of life…
  • 2018 International Congress

    DIRECT DBS: A Prospective, Multicenter Clinical Study with Double-Blinding for a Directional Deep Brain Stimulation Lead – Visualization of Optimal Directionally Stimulated Anatomy

    F. Steigerwald, J. Volkmann, C. Matthies, A. Dalal Kirsch, S. Chabardes, R. de Bie, PR. Schuurman, E. Moro, V. Fraix, S. Meoni, D. Blum, L. Juarez Paz, K. Wynants, N. Van Dyck (Würzburg, Germany)

    Objective: To visualize the volumes of activated tissue in relation to the neuroanatomy for the optimal stimulation parameters in Ring Mode (omnidirectional) stimulation in comparison…
  • 2018 International Congress

    Directional Lead Impedances and Their Possible Effects on Deep Brain Stimulation

    L. Juarez Paz, A. Dalal Kirsch, F. Steigerwald, C. Matthies, S. Meoni, V. Fraix, T. Ten Brinke, R. de Bie, K. Wynants, D. Blum, N. Van Dyck, PR. Schuurman, E. Moro, S. Chabardes, J. Volkmann (Valencia, CA, USA)

    Objective: The objective was to characterize the possible effects that directional leads impedances have on Deep Brain Stimulation (DBS) therapy. Background: DBS of the subthalamic…
  • 2018 International Congress

    Occurrence of dopaminergic adverse-events in patients that switched from entacapone to opicapone: The BIPARK-I open-label experience

    A. Ceballos-Baumann, K. Eggert, J. Ferreira, W. Poewe, O. Rascol, E. Arbe, J-F. Rocha, P. Soares-da-Silva (Munich, Germany)

    Objective: To assess the occurrence of dopaminergic adverse-events (AEs) in levodopa-treated Parkinson’s Disease (PD) patients that switched from entacapone (ENT) to opicapone (OPC) in the…
  • 2018 International Congress

    The BeyoND study: Design and baseline characteristics of a study evaluating the long-term safety of ND0612 for motor fluctuations in Parkinson’s disease

    W. Poewe, F. Stocchi, A. Espay, T. Rachmilewitz Minei, S. Oren, R. Case, K. Kieburtz, C. Olanow (Innsbruck, Austria)

    Objective: Describe the design and baseline characteristics of a long-term (1 year) study of 2 ND0612 dose regimens, with emphasis on systemic and local safety…
  • « Previous Page
  • 1
  • …
  • 1430
  • 1431
  • 1432
  • 1433
  • 1434
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley